GlassScriptPhysician profile
William Miles Beary
NPI 1598722993
$689.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $85.50 · 2021: $121 · 2022: $49.01 · 2023: $116 · 2024: $60.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $206.19 | 2019-2023 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.70 | 2019-2021 | |
| Abbvie INC. | $67.77 | 2021-2023 | Avycaz |
| Grifols USA, LLC | $58.05 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $48.46 | 2019 | |
| Pulmonx Corporation | $30.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.18 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $28.69 | 2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $24.76 | 2023 | Dupixent |
| Amgen INC. | $23.45 | 2023 | Tezspire |
| Astellas Pharma US INC | $18.24 | 2023 | Cresemba |
| La Jolla Pharmaceutical Company | $16.82 | 2019 | |
| Insmed, INC. | $16.33 | 2024 | Arikayce |
| Gilead Sciences, INC. | $15.34 | 2024 | |
| Shire North American Group INC | $11.68 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Beary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.